Background:
Ziyuglycoside I isolated from S. officinalis root, has anti-wrinkle activity, and increases the expression of type I collagen. Ziyuglycoside I could be used as an active ingredient for cosmetics[1].Ziyuglycoside I triggers cell cycle arrest and apoptosis mediated by p53, it can be a potential drug candidate for treating triple-negative breast cancer (TNBC)[2].
Ziyuglycoside I (5-160 μM; 24 hours) reveals a marked anti-proliferation activity with an IC50 value of 13.96 μM in MDA-MB-231 cells[2].Ziyuglycoside I (5-20 μM; 24 hours) induces MDA-MB-231 cell apoptosis by increasing the percentage of apoptotic cells from 2.43% to 44.76% at 20 μM[2].Ziyuglycoside I (5-20 μM; 24 hours) induces the cleavage of caspas-8, caspase-9, and caspase-3, up-regulates the pro-apoptotic protein Bax, and down-regulates anti-apoptotic protein Bal-2, dose-dependently reduces the level of mito-cyto c expression[2].
参考文献:
[1]. Kim YH, et al. Anti-wrinkle activity of ziyuglycoside I isolated from a Sanguisorba officinalis root extract and its application as a cosmeceutical ingredient. Biosci Biotechnol Biochem. 2008 Feb;72(2):303-11. Epub 2008 Feb 7.
[2]. Zhu X, et al. Ziyuglycoside I Inhibits the Proliferation of MDA-MB-231 Breast Carcinoma Cells through Inducing p53-Mediated G2/M Cell Cycle Arrest and Intrinsic/Extrinsic Apoptosis. Int J Mol Sci. 2016 Nov 22;17(11). pii: E1903
动态评分
0.0